The TSH receptor (TSHR) is constitutively active and is further enhanced by TSH ligand binding or by stimulating TSHR antibodies (TSHR-Abs) as seen in Graves' disease. TSH is known to activate the thyroid epithelial cell via both G␣s-cAMP/protein kinase A/ERK and G␣q-Akt/protein kinase C coupled signaling networks. The recent development of monoclonal antibodies to the TSHR has enabled us to investigate the hypothesis that different TSHR-Abs may have unique signaling imprints that differ from TSH ligand itself. We have, therefore, performed sequential studies, using rat thyrocytes (FRTL-5, passages [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] as targets, to examine the signaling pathways activated by a series of monoclonal TSHR-Abs in comparison with TSH itself. Activation of key signaling molecules was estimated by specific immunoblots and/or enzyme immunoassays. Continuing constitutive TSHR activity in thyroid cells, deprived of TSH and serum for 48 h, was demonstrated by pathway-specific chemical inhibition. Under our experimental conditions, TSH ligand and TSHRstimulating antibodies activated both G␣s and G␣q effectors. Importantly, some TSHR-blocking and TSHR-neutral antibodies were also able to generate signals, influencing primarily the G␣q effectors and induced cell proliferation. Most strikingly, antibodies that used the G␣q cascades used c-Raf-ERK-p90RSK as a unique signaling cascade not activated by TSH. Our study demonstrated that individual TSHR-Abs had unique molecular signatures which resulted in sequential preferences. Because downstream thyroid cell signaling by the TSHR is both ligand dependent and independent, this may explain why TSHR-Abs are able to have variable influences on thyroid cell biology. (Endocrinology 150: 519 -529, 2009) T he TSH receptor (TSHR) is a member of the seven-transmembrane receptor subfamily and mainly activates the classical G protein-coupled receptor (GPCR) effectors, G␣s and G␣q, and their complex signaling systems (1, 2) . Because multiple positive and negative feedback mechanisms are common to postreceptor signaling pathways, most are not considered as linear pipelines but as systems or cascades. They need to be viewed as intricate signaling networks containing multiple modules of protein-protein complexes that assemble at various intracellular compartments to process, integrate, and transmit information ultimately specifying a particular biological response. The TSHR has constitutive signaling activity and is further activated by TSH ligand binding or by unique stimulating autoantibodies to the TSHR (TSHR-Abs) seen in patients with Graves' disease. Therefore, inappropriate activation and/or inactivation of signaling cascades triggered by these different ligands may contribute to thyroid pathology in a way quite distinct from TSH.
The G␣s activities are largely mediated by an increase in adenylate cyclase (AC) activity, which generates intracellular cAMP leading to the direct activation of protein kinase A (PKA)-cAMP response element-binding protein (CREB) or either the PKA-dependent Ras family of GTP binding proteins (Rap)1-b-Raf-ERK-Ets-like transcription factor (Elk1) cascade or the PKAindependent exchange protein activated by cAMP (EPAC1)-Rap1b-ribosomal protein S6 kinase, 90 kD protein (Raf)-ERKElk1 signaling pathway to regulate thyroid function ( Fig. 1) (3, 4) . The ERK has been the subject of intense study and it is important to note that ERK is a downstream component of a well conserved signaling module that is more commonly activated by the Raf serine/threonine kinases, particularly c-Raf ( Fig. 1) (5, 6) . This Raf-MAPK kinase (MEK)-ERK pathway is also a key downstream effector of the Ras small GTPase, which requires receptor tyrosine kinase (RTK) activation by various growth factors (7) . It is, therefore, interesting that in TSHR signaling, ERK1/2 can also be activated by either the PKA-Rap1 or EPAC1-Rap1 pathways as depicted in Fig. 1 (8, 9) . Both Elk-1 and ribosomal protein S6 kinase, 90 kD protein (p90RSK) as well as immediate-early genes are important downstream transcription factors in these ERK1/2 activation pathways (10, 11) .
An alternate TSHR effector pathway, via G␣q, mediates the activation of the phospholipase C (PLC)-␤ and the G␤␥ subunit (12) . Among multiple isoforms, PLC␤1 and -3 are stimulated by G␣q, whereas PLC␤2 is stimulated by the G␤␥ subunit complex. Once activated, PLC hydrolyzes phosphatidylinositol (PI) bisphosphate (PIP 2 ) to inositol 3,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG) (13, 14) . Akt is activated as a result of PI3-kinase activity, because Akt requires the formation of the PI-3,4,5-trisphosphate molecule to be translocated to the cell membrane (15) and in the presence of PI-3,4,5-trisphosphate, Akt is then phosphorylated by another kinase called 3-phosphoinositide-dependent protein kinase-1 (PDK1), and is thereby activated (16) . The Akt signaling pathway is required most notably for cellular proliferation and survival (17, 18) . PI3 and DAG are also involved in the activation of Ca 2ϩ and protein kinase C (PKC) isoenzymes, respectively, whereas PDK1 kinase is involved in the activation of atypical PKC isoenzymes (16, 19) . Hence, PDK1 plays a central role in many signal transduction pathways involving Akt, PKC isoenzymes, p70 S6 kinase, and RSK (18, 20, 21) .
Activation of transcription factors of the nuclear factor B (NFB) in FRTL-5 cells by TSH or stimulating TSHR antibodies has been reported previously (22, 23) . NFB-activating agents can induce the phosphorylation of IB's, targeting them for rapid degradation through a ubiquitin-proteasome pathway, releasing NFB to enter the nucleus, where it regulates gene expression (24, 25) .
In addition to the TSH-or TSHR antibody-induced downstream TSHR signaling responses, each arm (G␣) of the effectors is under the influence of a wide variety of growth factors (26, 27) (Fig. 1) . These factors work via MAPK cascades, which are key signaling systems involved in the regulation of normal cell proliferation, survival, and differentiation (2, 28) .
The recent development of various types of monoclonal antibodies to the TSHR has enabled us to investigate their potential signaling events in a model system providing information quite distinct from previous reports using polyclonal sera from patients with TSHR-Abs. Monoclonal TSHR-Abs, which either stimulate as TSH agonists or block TSH action, have begun to be characterized previously, but their signaling cascades have not been evaluated in depth (29 -34) . In addition, TSHR-Abs of neutral type have been defined as binding to the receptor without any influence on cAMP generation (35) and what role they play in the signal transduction remains completely unknown. We hypothesized that different TSHR-Abs might have unique signaling imprints at the TSHR altering cellular functions in distinct patterns not seen with TSH itself. Using rat thyrocytes (FRTL-5) as targets, we have, therefore, performed sequential studies to examine selected signaling events and their downstream effectors initiated by a series of monoclonal antibodies to the TSHR. These studies were not envisaged as determining new signal transduction pathways but rather as exercises in illuminating differences between TSHR-Abs and TSH ligand. Our observations demonstrated that stimulating TSHR-Abs used signaling pathwayssimilartoTSHactivationmodulesdependingonthestrength of the signals generated. Some blocking and neutral TSHR-Abs, although previously considered as nonsignaling, also showed unique molecular signatures affecting c-Raf-ERK-p90RSK signal transduction pathways, indicating that these antibodies have the potential to act as weak agonists. Because thyroid cell proliferation is one of the downstream effector mechanisms of signaling events, our studies also showed that both G␣s and G␣q signaling networks contributed to this process. Forward acceleration or interruption of signaling networks by TSHR-Abs may, therefore, explain some of the variable thyroid pathology observed in patients with Graves' disease.
Materials and Methods

Cell cultures
FRTL-5 rat thyroid cells were used as the model system (28, 36 when compared with normal cells (37) . In particular, TSH signaling may be PKA independent in the FRTL-5 cell (28) . Nevertheless, in the absence of a more normal thyroid cell line, the FRTL-5 served our purpose well. Cells were diploid and between their fifth and 20th passage after receipt. The doubling time of these cells was 36 Ϯ 6 h when cultured in the presence of bovine TSH, and proliferation was absent without TSH. Cells were grown as previously described (28) 
Culture conditions for stimulations
To obtain a good timeframe for synchronizing signaling events to basal levels of signaling molecules, we starved cells for different time points. We started with 1 h starvation and then went for 24 and 48 h and finally for 72 h. After 24 -72 h starvation, FRTL-5 cells exhibited fewer Akt responses but produced more responses on multiple signaling events, particularly PKC and PKA, and so 48 h starvation was chosen. All of the above conditions had no effect on the c-Raf/ERK/p90RSK pathway or NFB activities. In two separate experiments at two different passages, both FRTL-5 and JPO9 cells demonstrated similar reproducible data (not illustrated).
TSHR antibodies
The monoclonal TSHR antibodies examined are listed in Table 1 . They included three stimulating (M22, MS1, and RSR-12), two blocking (Tab-8 and RSR-B2), and two neutral (7G10, Tab-16) monoclonal antibodies. M22 and the RSR monoclonals were kindly supplied by Dr. B. Rees Smith (RSR Ltd., Cardiff, Wales, UK). The remaining monoclonal antibodies have been described previously (30, 31, 33, 34) . Each of these antibodies was used to stimulate FRTL-5 cells to study signal transduction mechanisms.
Treatment and cell lysates
Before stimulation, medium was discarded from the 60-mm culture dishes, and the cells were washed three times with a fresh medium containing Hanks' balanced salt solution (HBSS; Life Technologies, Inc. Laboratories, Grand Island, NY). After the indicated stimulations in fresh modified Ham's F12 basal medium, cells were washed twice with ice-cold PBS (pH 7.2) without calcium and magnesium (Mediatech), scraped into cold Phosphosafe lysis buffer (EMD Biosciences, San Diego, CA) containing proteinase inhibitor cocktail (Complete, Mini; Roche Applied Science, Indianapolis, IN) and phenylmethylsulfonyl fluoride (Sigma) and sonicated for 10 -15 sec. After measuring protein concentrations by the Bradford or BCA assay kits (Bio-Rad Laboratories, Hercules, CA), samples were boiled for 5 min in NuPAGE LDS sample buffer with reducing agent (Invitrogen, Carlsbad, CA). The samples were then centrifuged at 13,000 rpm for 5 min at room temperature, and the supernatants were removed and stored in aliquots at Ϫ80 C. Because culture conditions may influence signaling events, the same condition was applied to all treatments and was strictly maintained in each experiment. All stimulation experiments were performed at least twice at two different time points.
Detection of signaling molecules by immunoblot
Sixty micrograms of total proteins were resolved by 4 -15% gradient SDS-PAGE mini-gel (Bio-Rad) and transferred onto polyvinylidene difluoride membranes (Bio-Rad). Antibodies that recognize signaling molecule-specific phosphoproteins or non-phosphoproteins were immunodetected according to the instructions provided with the phosphospecific antibody kits (Cell Signaling Technology, Beverly, MA). Antibody substrate reaction was performed by SuperSignal chemiluminescence kit (Pierce, Rockford, IL) and was visualized on x-ray film using variable exposures (38) . The same blots were used repeatedly after stripping off and reprobing with different antibodies. Relative quantification of signal intensities on x-ray film was analyzed using scanning densitometry (AlphaImager 2200; Alpha Innotech, San Leandro, CA).
Two pathway-specific antibody sampler kits containing ERK (pcRaf, Ser338; pMEK1/2, Ser217/221; pERK1/2, Thr202/Tyr204; pElk-1, Ser383; pp90RSK, Ser380) and PKC (pan pPKC␤⌱⌱ Ser660, pPKC␣/␤⌱⌱ Thr638/641, pPKC␦ Thr505, pPKC␦ Ser643, pPKD/PKC Ser744/748, pPKD/PKC Ser916, Thr538, pPKC/ Thr410/403) (Cell Signaling) were used. pAkt (Ser473), pPKC-/ (⌻hr410/403), pPKA-C (Thr197), pCREB (Ser133), non-phospho-PKAc␣, pERK1/2 (Thr202/Tyr204), pp90RSK (Ser380), and pNFB (p65, Ser536) were also from Cell Signaling. Nonphosphorylated mouse monoclonal ␤-actin and unrelated control monoclonal (IgG2, -chain) antibodies were from Sigma and BD Biosciences (Franklin Lakes, NJ), respectively. Fold stimulation was determined by intracellular cAMP assay using CHO cells expressing human TSHR, and blocking was expressed as the percent reduction of cAMP produced by test antibodies in the presence of TSH divided by cAMP produced by medium (29, 34) . ND, Not determined.
a NC35 indicates that the antibody-binding target was CHO-NC35 cells expressing a TSHR variant lacking residues 316 -366 and included amino acid substitutions at 367-369 (58).
Pathway-specific inhibitors
All inhibitors were purchased from EMD Biosciences (Gibbstown, NJ). H89, GF109203X, LY294002, and PD98059 were used to inhibit PKA, PKC, PI3-kinase (Akt), and MEK/ERK activities, respectively.
PKA and PKC activity assays
Determination of PKA and PKC activity in whole-cell lysates was achieved with commercial enzyme immunoassay (EIA, StressXpress; Stressgen Bioreagents, Ann Arbor, MI) kits according to the manufacturer's instructions. The assay was based on a solid-phase EIA that used a specific synthetic peptide as a substrate for kinases and polyclonal antibodies that recognized the phosphorylated forms of the substrate. These assays were designed for the analysis of PKA and PKC activities in the solution phase. Treated cells with specific agents were lysed after the indicated time points. Five micrograms of total protein extracts were used for the assays. Results are expressed as relative units of absorbance (450 nm).
cAMP assay FRTL-5 (80% confluent) and JPO9 (3 ϫ 10 4 ) cells were used for intracellular cAMP levels measured by EIA (Assay Designs, Inc., Ann Arbor, MI, or Amersham cAMP Biotrak EIA System, GE Healthcare Bio-Sciences Corp., Piscataway, NJ) using polyclonal antibody to cAMP to bind, in a competitive manner, the cAMP in the standards or samples or a conjugate molecule that had cAMP covalently attached. The intensity of the bound color was inversely proportional to the concentration of cAMP in either standards or samples. In each treatment, 2 mM 3-isobutyl-1-methylxanthine (Sigma) in the basal medium was used for measuring intracellular cAMP levels.
MTT cell proliferation assay
An MTT [3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl 2H-tetrazolium bromide] proliferation assay was carried out according to instructions provided (Sigma). Cell proliferation experiments were performed in a 96-well plate in triplicate in basal medium without any hormones. Cells (3 ϫ 10 3 per well) were seeded and maintained in 200 l 6H medium in a humidified incubator. Cells were then made quiescent by switching to medium containing 5H plus 5% BCS for 3 d and synchronized by starvation in the basal medium containing 0.3% BSA for 2 d. The colorimetric MTT proliferation assays were performed at d 3 after treatment. MTT (400 g/ml) was added to each well, incubated for 3 h, and solubilized with 0.04 M HCl/isopropanol for 30 min. The OD was determined using a spectrophotometer (DTX 880 Multimode Detector; Beckman Coulter, Fullerton CA) at a wavelength of 570 nm.
To ensure reproducibility, all stimulation and inhibition experiments were repeated twice, and the basal level of analytes in all assays used, when analyzed either densitometrically or colorimetrically, were comparable (coefficient of variation ϭ 4.6 -11%).
Statistical analysis
The paired t test was used to evaluate the significance of differences in means for continuous variables. A P value of Յ0.05 was used to determine statistical significance. Data are presented as the mean Ϯ SD of the mean. 
Results
Traditional readouts: cAMP generation and cell proliferation
We first characterized the TSH and TSHR antibody responses in rat thyroid FRTL-5 cells and CHO cells, under our defined experimental conditions, by using intracellular cAMP accumulation and cell proliferation as endpoints ( Table 1 ). As expected from previous studies, both TSH and three stimulating antibodies to the TSHR-induced cAMP generation and enhanced proliferation of thyroid cells (Figs. 2 and 3 ). Both induced intracellular production of cAMP in a dose-and time-dependent manner and in high concentrations suppressed the thyroid cell responses (Fig. 2, A and B) . When fixed concentrations of TSH (1 mU/ml) and TSHR-Abs (1 g/ml) were applied, stimulators and one blocker exhibited significantly higher levels of cAMP than medium alone (TSH, P Ͻ 0.007; M22, P Ͻ 0.01; RSR-12, P Ͻ 0.01, MS1, P Ͻ 0.001; RSR-B2, P Ͻ 0.009). TSHR neutral antibodies showed no effect on cAMP production (P ϭ not significant). Using a fixed concentration of TSH (1 mU/ml), the ligand response was first detectable at 3 min in thyroid cells with peak levels reached after 30 min stimulation (Fig. 2B) . With a fixed concentration of TSHR stimulating antibody (M22, 1 g/ml), a slower response was seen, but the peak was also reached by 30 min (Fig. 2B) .
After 48 h serum deprivation, human TSHR-expressing CHO cells were also treated with a fixed concentration of TSH (1 mU/ml) or antibodies (1 g/ml) over time, and a similar but more rapid response was observed by the human stimulating antibody (M22) (Fig. 2C ) compared with the rat TSHR (Fig. 2B) . B2 blocking antibody (1 g/ml) also induced cAMP production as seen in the rat cells. Increasing concentrations of B2 showed a peak at 1 g/ml followed by a suppressive effect at 10 g/ml. This finding was different from that of our earlier observations where cells were not starved for 2 d (29) . Serum starvation decreased the basal cAMP and thus caused a detectable increase in cAMP production similar to what we observed in FRTL-5 cells. By contrast, an unrelated control antibody produced no effect on cAMP induction.
Increasing concentrations of TSH and TSHR-Abs showed different effects on the rat thyroid cell proliferation assay. The highest proliferation was observed at 1 mU/ml TSH and 1 g/ml antibodies. A robust increase in proliferation was produced by stimulating antibodies. and much less robust stimulation was seen with some blocking and neutral antibodies (Fig. 3) . At a fixed concentration, TSH (1 mU/ml) stimulating and blocking antibodies (1 g/ml) activated thyroid cell proliferation (TSH, P Ͻ 0.0004; M22, P Ͻ 0.0005; RSR-12, P Ͻ 0.0004; MS1, P Ͻ 0.0003; RSR-B2, P Ͻ 0.0008; Tab-8; P Ͻ 0.001) when compared with the basal medium alone or control antibody (Fig. 3) . Interestingly, one of the neutral and one of the blocking antibodies (Tab-8 and Tab-16) that showed no significant increase in cAMP production consistently induced thyroid cell proliferation (Tab-16, P Ͻ 0.002), whereas another (7G10) exhibited suppressive effects (P Ͻ 0.02) at 10 g/ml. This suggested that different pathways to proliferation via G␣q existed in this cell model. However, overall, the results of the cell proliferation studies mostly paralleled the cAMP responses with down-regulation of the proliferative responses seen with concentrations greater than 10 mU/ml TSH or 10 g/ml antibody (Fig. 3) .
These experiments confirmed that our cell culture conditions were appropriate for the subsequent signal transduction studies.
Constitutive activity of Akt, PKA/CREB, PKC, NFB, and c-Raf/ERK/p90RSK
To define the activity and stability of selected key signaling molecules, we next performed time-dependent studies to examine their constitutive activity under our experimental conditions. Quiescent and starved cells were left untreated in the fresh basal medium at intervals for up to 60 min and then lysed as described. Immunoblot analyses of these lysates exhibited decreased expression of c-Raf/ERK/p90RSK, PKC-/, and Akt in a timedependent fashion, whereas PKAc␣, PKAc (phospho), CREB, and NFB activities remained unchanged (Fig. 4, A and B) . The constitutive activity of ERK and c-Raf decreased faster than p90RSK or Akt. To further confirm key signaling cascades unique to FRTL-5 cells and to define their specificities, we examined the effect of molecular inhibitors on the different signaling cascades, being aware that not all such inhibitors are always totally specific. FRTL-5 cells were treated with a fixed concentration of inhibitor and analyzed at three time points (30 min and 1 and 2 h). Cell lysates were then immunoblotted and analyzed by antibodies specific for phosphoproteins. All the inhibitors used in this study produced a reduction in the phosphorylation of their specific proteins (Fig. 4, C and D) . Inhibitors specific for PI3-kinase uncovered multiple feedback mechanisms in quiescent thyroid cells. The PI3-kinase inhibitor (LY294002; 1 M) suppressed Akt activity but activated signaling cascades including ERK/p90RSK, PKA/CREB, PKC-/, and NFB, whereas the PKA inhibitor (H89; 50 M) increased the constitutive activity of Akt. The PKC inhibitor (GF109203X; 50 M) reduced PKC-/ activity and also suppressed c-raf/ERK/p90RSK (Fig. 4, C and .0, and 10 g/ml) in the basal medium. At a fixed concentration, TSH (1 mU/ml) stimulating and blocking antibodies (1 g/ml) demonstrated significantly higher cell proliferation (TSH, P Ͻ 0.0004; M22, P Ͻ 0.0005; R12, P Ͻ 0.0004; MS1, P Ͻ 0.003; B2, P Ͻ 0.0008; T8; P Ͻ 0.001) than medium alone (basal) or a control antibody (Cont; 1 g/ml). One of the neutral (T16; 1 g/ml) antibodies also showed significantly higher proliferation (P Ͻ 0.001), whereas 7G showed suppressive effects (P Ͻ 0.02) at a higher concentration (10 g/ml). These experiments were repeated twice in triplicate.
D). To show effects of ERK on other pathways, we also used a MEK1/2 inhibitor (PD98059; 50 M), the immediate upstream regulator of ERK. This inhibitor suppressed ERK and its downstream molecule p90RSK. All the inhibitors used with rat thyroid cells were also used to suppress kinase activities in human TSHRtransfected CHO cells. Unlike the potentially different signaling cross talk and/or feedback loops, these inhibitory effects were no different from those seen in the FRTL-5 cells. These multiple signaling events by different pathway-specific inhibitors indicated that cross talk and/or feedback mechanisms were essential steps in the fine tuning of the signaling cascades and were not apparently specific for thyroid cell function.
TSH activates CREB but not the PKA/ERK or c-Raf /ERK/ p90RSK pathway
The ERK pathway was analyzed by phosphospecific sampler antibodies before and after exposure to TSH (Fig. 5, A and B) . The constitutive expression level of phosphorylated c-Raf, ERK, and p90RSK was higher than MEK (immediately upstream of ERK) and Elk1 (downstream of ERK) in the rat thyroid cells. Because 1 mU/ml TSH and 1 g/ml TSHR-Abs showed comparable effects on cAMP and proliferation indices, we used these concentrations for subsequent time-response immunoblot experiments. TSH (1 mU/ml), a dose that induced thyroid cell proliferation, did not increase the activity of ERK even after 60 min exposure, and the constitutive loss described earlier continued (Fig. 5, A and B) . The loss of ERK activity paralleled the p90RSK activity. Hence, a proliferative concentration of ligand-dependent TSHR stimulation did not enhance the activity of the c-Raf/ ERK/p90RSK pathway, but CREB, a downstream molecule of the PKA pathway, indicated higher activity over time. Because the constitutive activity of PKA was high in these quiescent cells, it was difficult to discern changes by immunoblot or bioassay in this model (Figs. 5 and 6 ). Nevertheless, small TSH-induced increases were seen by 30 min, and such small PKA dynamic changes may have been sufficient to phosphorylate downstream molecules such as CREB.
TSH activates the Akt and PKC pathways
Both time-dependent and dose-dependent studies demonstrated that TSH also activated Akt and PKC effectors (Figs. 5  and 6 ). PKC-/, atypical isoforms, were identified as highly expressed phosphoproteins in rat thyroid cells (Figs. 5 and 6 ). Other highly expressed classical and novel phosphorylated PKC isoforms such as ␤⌱⌱, ␣/␤⌱⌱, ␦, and were also detectable (not illustrated). A robust increase in Akt and PKC-/ activity was observed by 30 min TSH stimulation (Fig. 5) . Increased PKC activity was also confirmed by enzyme assay (Fig. 7) . NFB showed a small increase in activity after exposure to TSH in line with the increased PKC levels. These observations indicated that CREB, Akt, and PKC-/ were important molecules involved in TSH-induced thyroid cell signaling cascades. The PKA independence of these cascades has been previously reported in these cells (28) .
TSHR-stimulating antibodies activate TSH signaling pathways
TSHR-stimulating antibodies showed a signal pattern generally similar to TSH-mediated changes (Fig. 6) . Each of the three stimulating antibodies activated Akt and PKC-/ at variable concentrations and time points. For example, both M22 and MS1 antibodies induced an increase in Akt and PKC-/ at a dose of 0.1 g/ml after 1 h stimulation, whereas R-12, which was much less active, increased Akt and PKC-/ activities at a maximum dose of 10 g/ml. None of the stimulating antibodies activated the c-Raf/ERK/p90RSK pathway. Rather, they produced a dose-dependent suppressive effect on this pathway as seen with TSH (Fig. 6) . However, M22 showed a marked increase in PKA activity and repeatedly exhibited an increase in p90RSK presumably via a different pathway. However, as far as activation of CREB was concerned, whereas M-22 and MS-1 induced CREB in the same way as seen with TSH, TSHR-Ab R-12 had no such effect.
TSHR-blocking antibodies induce signaling cascades indicative of weak agonist activity
Designated TSHR-blocking antibodies showed a diverse effect on multiple signaling cascades in keeping with their known weak agonist activity. RSR-B2, which induced low-level cAMP generation and cell proliferation (Figs. 2 and 3) , increased Akt, CREB, c-Raf, and ERK (Fig. 8A) , whereas Tab-8 activated PKA and PKC (Fig. 8A ), in line with their proliferative effects seen earlier (Fig. 3) .
TSHR-neutral antibodies induce different signaling cascades
The two designated neutral antibodies were not neutral in their signaling activity but produced different signaling events dose dependently. One of them (Tab-16) showed modest activation of many signaling molecules such as Akt, PKC, PKA, CREB, ERK, and p90RSK, whereas the other (7G10) tended to consistently reduce constitutive signaling molecular activities as seen with PKC, c-Raf, ERK, and p90RSK (Fig. 8B) . Control antibody did not induce any effect on these effectors (Fig. 8C) . , and M22 over a 60-min incubation showed similar changes in signaling molecules as seen with TSH ligand in these representative immunoblots. M22 produced dosedependent significant increases in Akt, PKA, and CREB activities compared with TSH and the other antibodies. These dose-response studies were repeated twice.
Discussion
The overall aim of our studies was to examine the signal transduction pathways initiated by antibodies to the TSHR in comparison with each other and with TSH itself. We began with the hypothesis that stimulating TSHR-Abs would act just like TSH and that blocking and neutral antibodies would produce no signal transduction activities. In fact, we found monoclonal examples of each of these varieties of TSHR-Abs that were able to initiate complex signaling cascades. As expected, both cAMP generation and cell proliferation assays identified stimulating antibodies as true TSH agonists. However, one apparent TSHblocking antibody induced the generation of cAMP both in FRTL-5 and CHO cells expressing human TSHR and induced cell proliferation in FRTL-5 cells. This finding was in agreement with earlier observations where blocking antibodies were proposed as weak agonists (39, 40) . In addition, we found evidence that a totally neutral TSHR-Ab was also capable of initiating signal transduction cascades. These data strongly suggested that a variety of changes in molecular shape of the TSHR induced by antibody binding would result in the initiation of signaling.
To determine key signaling molecules in quiescent thyroid cells, we first characterized the constitutive activity of different signaling molecules in a time-dependent fashion. We identified several key modules that demonstrated reduced activities when rat thyroid cells were deprived of TSH and serum. We then illustrated continuing system cross talk, i.e. feedback inhibition or activation of one signaling module by other signaling modules, using pathway-specific inhibitors (41) . For example, a PI3-kinase inhibitor reduced its downstream effector, Akt, but activated the ERK-p90RSK pathway along with PKA/CREB and PKC. These findings indicated that ERK-p90RSK could be controlled by either PKA or PKC or by both. PKA-dependent and -independent ERK activation and growth factor RTK-induced ERK activation have already been described in thyroid cells (7, 28) . Because PI3-kinase inhibition activated PKC/ERK/p90RSK and the PKC inhibitor did the opposite, we reasonably assumed that PKC also controlled the ERK-p90RSK pathway.
We saw no effect of TSH on ERK activation. In FRTL-5 cells, ERK activation by cAMP is independent of PKA and linked to Rap1 activation through EPAC (3, 4, 9, 28) . However, in other models, TSH or forskolin activated Rap1 but failed to activate ERK (9, 42) . Because different results have been obtained in different cell model systems (1, 43) , the role of ERK in the proliferation of normal thyrocytes still remains unclear. Because cAMP (via G␣s) and PI3-PDK1-PKC (via G␣q), and Ras (via RTK) are all able to regulate ERK phosphorylation, we assume that the ERK pathway in FRTL-5 cells is controlled by at least three individual modular networks, which have both forward activation and feedback attenuation and are under the influence of multiple cross talk. This may explain why our study did not produce steady-state ERK activation with TSH.
Our study confirmed earlier observations that TSH activated Akt (44) and that this activation occurred via PI3-kinase. Suh et al. (44) PKA and PKC activity assessed by EIA. In our model system, TSH (1 mU/ml) did not activate PKA enzyme activity, whereas the M22 TSHR-stimulating antibody (1 g/ml) did demonstrate a highly significant increase (P Ͻ 0.0001). R12 (P Ͻ 0.013) and MS1 (P Ͻ 0.03) stimulating antibodies showed significantly reduced activities. Both neutral antibodies also exhibited similar effects (T16 and 7G, P Ͻ 0.02).
Although blocking antibodies did not produce any significant effects. In contrast, both TSH (P Ͻ 0.0005) and TSHR-stimulating antibodies increased PKC (M22, P Ͻ 0.001; R12, P Ͻ 0.003) activity significantly. One of blocking (B2, P Ͻ 0.0001) and both neutral (T16, P Ͻ 0.0001; 7G, P Ͻ 0.0002) antibodies also demonstrated a significant increase in PKC activity when compared with the medium alone (basal) or a control monoclonal antibody (cont). The experiments were repeated three times and confirmed the illustrated findings. was no doubt that under our conditions Akt was activated by TSH. Indeed, the TSH effect on Akt phosphorylation paralleled that of the proliferation index indicating that this pathway may be an important signaling module contributing to cell proliferation. Interestingly, the mitogenic effect of TSH on Akt also correlated well with cAMP levels similar to that observed by others (37) . It is most likely that some activation of Akt may arise from cAMP through EPAC in FRTL-5 cells as suggested by Mei et al. (45) . Although our study was unable to show a notable TSH-induced increase in PKA activity, CREB, a key downstream molecule of PKA, was found activated by TSH, showing that CREB is one of the important signaling effectors in FRTL-5 thyrocytes (46) . Clearly, these studies indicated that a complex network was involved in TSH-induced Akt and CREB activation in a cell-specific manner. It is well known that TSH stimulates PLC and increases intracellular free Ca 2ϩ concentrations and DAG (16, 19) . Kim et al. (47) confirmed these findings and found that TSH activated PKC via PC-PLC-DAG, which required Rho activation but not PKA. In the present study, TSH activated PKC as evidenced by both PKC enzyme and immunoblot assays. Using a phosphospecific PKC antibody, we identified PKC-/ as highly expressed in these cells on activation by TSH. Dominance of PKC-and PKC-␦ has been described in PCCL3 and PCE1Araf thyrocytes (48) . Because TSH activated cAMP, CREB, Akt, and PKC and also induced FRTL-5 proliferation, these findings demonstrated the multiple mitogenic factors involved in thyroid cell activation and proliferation.
The naturally conformed TSHR is most effectively presented as an autoantigen to the immune system, causing the production of stimulating TSHR-Abs. Accumulating evidence indicates that stimulating TSHR-Abs, either from Graves' patients or animal models of the disease, recognize conformational binding sites on the ␣-subunit involving the leucine-rich repeats. Recently, Sanders and co-workers (49) defined the atomic structure of human stimulating TSHR antibody (M22) used in our studies, and they found that the amino acids in the TSHR ectodomain that determined the bioactivity of the antibody did not appear to be important for TSH binding and stimulation. Most of the amino acids important for M22 interactions were, however, also found to be important for the activity of six other stimulating monoclonals. They concluded that amino acid differences in the binding epitope were probably responsible for differences in the relative biological activities of the antibodies. Our study of three stimulating monoclonals, which showed some variation in their patterns of signal transduction, was also consistent with this conclusion. These data, therefore, suggested that different stimulating antibodies interacted with the same region of the TSHR, but there were likely to be subtle differences in the actual amino acids that made contact with the different stimulators.
Although our stimulating antibodies used primarily TSH signaling pathways, there were differences in signaling activities and signal strengths. Most importantly, the M22 antibody, which had the highest affinity for the TSHR, demonstrated significantly increased cAMP/PKA/CREB activity as well as Akt and PKC phosphorylation, which paralleled a high proliferation index. Because TSH activated CREB to only a modest degree, there were subtle differences in PKA/CREB activity induced by stimulating antibodies, suggesting that antibody binding to amino acids not contacted by TSH on the TSHR may be responsible for these effects. Furthermore, crystal structure studies of the binding site topography of stimulating M22 antibody indicated that electrostatic potentials were also different from that of TSH binding and may induce different effects (50) . In particular, signaling differences between TSH and M22 may be impacted by amino acid arginine at position 255 in the TSHR ectodomain, which was identified as an important site for interaction with M22 but not with TSH. This may be responsible for p90RSK activation, suggesting that M22 may also have activated additional signaling modules for downstream ERK regulation.
There are also antibodies that reduce TSH action at the TSHR or decrease its constitutive activity without a potent signaling capacity (51, 52) . Igs from Graves' and autoimmune (Hashimoto's) thyroiditis patients have also recently been shown to compete with a blocking monoclonal antibody to the N terminus of the TSHR ␤-subunit (amino acids 382-415) (53) . Hence, blocking antibodies are most likely heterogeneous, and their epitopes may lie broadly upstream of the ␣-subunit or downstream to the ␤-subunit (54). To help determine their functional consequences, we characterized signaling molecules in exposed rat thyroid cells. Most striking was that both TSHR-blocking antibodies (Tab-8 and RSR-B2) that we examined not only resulted in signal molecule activation but they also showed different pathway dominance. RSR-B2 activated the c-Raf/ERK/CREB pathway but not p90RSK, whereas Tab-8 did not activate c-Raf/ERK but activated p90RSK. Although both of these antibodies recognize conformational epitopes, these findings may arise from differences in their binding domains. Alternatively, the differences may be due to interference with the constitutive activity of the TSHR. Interestingly, one of the blocking TSHR-Abs (RSR-B2) induced a small increase in cAMP levels that was paralleled by increased cell proliferation, indicating that c-Raf/ERK and cAMP/CREB activation may have contributed to this proliferation. Recently, two independent groups identified blocking antibodies that suppress the constitutive activity of TSHR and cAMP generation (52, 55) . Indeed, these findings together with ours are in agreement with the hypothesis that the blocking antibodies may have influenced thyrocyte functions by altering multiple signaling mechanisms. Hence, these varieties of blocking antibodies could be considered as heterotopic allosteric modulators causing either activation or inhibition of TSHR activities. More study is necessary to correlate the effector mechanisms used by these antibodies with their different epitopes.
A third type of TSHR-Ab, the neutral TSHR-Abs, has also been recognized (51, 56) . Such antibodies have no influence on TSH binding (57) . It has, therefore, been assumed that neutral TSHR-Abs should have no influence on TSHR action and are of no clinical import. With the aim of examining the role these neutral antibodies may play in thyroid biology, we characterized their influence on signaling cascades and downstream effectors. We identified two separate mechanisms working in the rat thyroid cells when exposed to two neutral antibodies (7G10 and Tab-16). 7G10 suppressed multiple signaling modules, including cell proliferation, whereas Tab-16 caused activation of many of them paralleled with cell proliferation. However, both failed to inhibit TSH binding (by definition), and both failed to activate cAMP production. The amino acid sequences for these neutral antibody binding sites have already been described by us and other groups (30) . 7G10 recognized 322-341 and Tab-16 identified 337-356 amino acid residues. Both of them failed to recognize CHO-NC35 cells expressing a TSHR variant lacking the cleaved region (30, 58) . Because an overlap of five amino acids (337-341 residues) in these two antibody binding sequences exists, we suggest that the last 16 amino acids (341-356) may be critical to signal activating events. These findings raise the possibility that multiple domains in this molecular stretch of the TSHR may exist that suppress or stimulate the TSHR. Certainly, neutral antibodies that bind to the uncleaved region appear capable of initiating a signal.
In conclusion, stimulating antibodies used signaling pathways similar to the TSH activation modules contributing to cell activation and growth. Both TSH-blocking and neutral TSHR antibodies distinguished different signaling networks and resulted in variable signal responses, indicating that some may be weak agonists or inverse agonists. These observations help explain how TSHR-Abs may contribute to different clinical phenotypes in autoimmune thyroid disease.
